Fang Chen

Ms. Fang Chen

Student at South China Agricultural University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2021 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
CMChuang Ma
Chuang Ma
Fang ChenFang Chen
Fang Chen
XSXin Song
Xin Song
MCMing Chen
Ming Chen
LGLili Gao
Lili Gao
Shengzhong LiuShengzhong Liu
Shengzhong Liu

1 November 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BLBo Li
Bo Li
ZZZhe Zhang
Zhe Zhang
JZJian-Feng Zhang
Jian-Feng Zhang
JLJie Liu
Jie Liu
XZXiang-Yi Zuo
Xiang-Yi Zuo
YTYouzhi Tang
Youzhi Tang

29 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
HFHan-Qing Fang
Han-Qing Fang
JZJie Zeng
Jie Zeng
SWShou-Kai Wang
Shou-Kai Wang
XWXiao Wang
Xiao Wang
Fang ChenFang Chen
Fang Chen
YTYouzhi Tang
Youzhi Tang
A series of novel pleuromutilin derivatives containing nitrogen groups on the side chain of C14 were synthesized under mild conditions. Most of the synthesized derivatives displayed potent antibacterial activities. Compound 9 was found to be the most active antibacterial derivative against MRSA (MIC = 0.06 μg/mL). Furthermore, the result of time-kill curves showed that compound 9 had a certain inhibitory effect against MRSA in vitro. Moreover, according to a surface plasmon resonance (SPR) study, compound 9 (KD = 1.77 × 10−8 M) showed stronger affinity to the 50S ribosome than tiamulin (KD = 2.50 × 10−8 M). The antibacterial activity of compound 9 was further evaluated in an MRSA-infected murine thigh model. Compared to the negative control group, tiamulin reduced MRSA load (~0.7 log10 CFU/mL), and compound 9 performed a treatment effect (~1.3 log10 CFU/mL). In addition, compound 9 was evaluated in CYP450 inhibition assay and showed only moderate in vitro CYP3A4 inhibition (IC50 = 2.92 μg/mL).

3 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
YHYuhan Hu
Yuhan Hu
Fang ChenFang Chen
Fang Chen
KZKexin Zhou
Kexin Zhou
ZZZhe Zhang
Zhe Zhang
FLFei Li
Fei Li
ZJZhen Jin
Zhen Jin
The novel pleuromutilin derivative, which showed excellent in vitro antibacterial activity against MRSA, 22-(2-(2-(4-((4-(4-nitrophenyl)piperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)acetamido)phenyl)thioacety-l-yl-22-deoxypleuromutilin (Z33), was synthesized and characterized in our previous work. In this study, the preliminary pharmacodynamics and safety of Z33 were further evaluated. In in vitro antibacterial activity assays, Z33 was found to be a potent bactericidal antibiotic against MRSA that induced dose-dependent growth inhibition and long-term post-antibiotic effect (PAE). The drug-resistance test demonstrated that Z33 possessed a narrow mutant selection window and lower propensities to select resistance than that of tiamulin. Cytochrome P450 (CYP450) inhibition assay determined that the inhibitory effect of Z33 was similar to that of tiamulin against the activity of CYP3A4, and was lower than that of tiamulin on the activity of CYP2E1. Toxicity determination showed that both Z33 and tiamulin displayed low cytotoxicity of RAW264.7 cells. Furthermore, Z33 was found to be a high-security compound with a 50% lethal dose (LD50) above 5000 mg/kg in the acute oral toxicity test in mice. In an in vivo antibacterial activity test, Z33 displayed better therapeutic effectiveness than tiamulin in the neutropenic mouse thigh infection model. In summary, Z33 was worthy of further development as a highly effective and safe antibiotic agent against MRSA infection.

1 August 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Fang ChenFang Chen
Fang Chen
MWMeng-Chao Wei
Meng-Chao Wei
YLYi-Dan Luo
Yi-Dan Luo
ZJZhen Jin
Zhen Jin
YTYouzhi Tang
Youzhi Tang
Tetracycline (TET) has been widely used in the treatment of Streptococcus suis (S. suis) infection. However, it was found that the efficacy of many antibiotics in S. suis decreased significantly, especially tetracycline. In this study, GML-12 (a novel pleuromutilin derivative) was used in combination with TET against 12 S. suis isolates. In the checkerboard assay, the TET/GML-12 combination exhibited synergistic and additive effects against S. suis isolates (n = 12). In vitro time-killing assays and in vivo therapeutic experiments were used to confirm the synergistic effect of the TET/GML-12 combination against S. suis strains screened based on an FICI ≤ 0.5. In time-killing assays, the TET/GML-12 combination showed a synergistic effect or an additive effect against three isolates with a bacterial reduction of over 2.4-log10 CFU/mL compared with the most active monotherapy. Additionally, the TET/GML-12 combination displayed potent antimicrobial activity against four isolates in a mouse thigh infection model. These results suggest that the TET/GML-12 combination may be a potential therapeutic strategy for S. suis infection.